Iopofosine i-131 is under clinical development by Cellectar Biosciences and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Iopofosine i-131’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 08 Sep 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Iopofosine i-131 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Iopofosine i-131 overview

Iopofosine I-131 (CLR-131) is under development for the treatment of refractory and relapsed multiple myeloma,chronic lymphocytic leukemia, Hodgkin lymphoma, small lymphocytic lymphoma, lymphoplasmacytic lymphoma (LPL), central nervous system lymphoma, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), solid tumors,neuroblastoma, pediatric diffuse intrinsic pontine glioma, sarcomas including rhabdomyosarcoma, Ewing's sarcoma, osteosarcoma, lymphomas and malignant brain tumors, high-grade glioma, diffuse large B-cell lymphoma (DLBCL), head and neck cancer squamous cell carcinoma. It is a radiolabeled compound which is administered by intravenously. CLR-131 is comprised of PLE, 18-(p-[I-131] iodophenyl) octadacyl phosphocholine, covalently labelled with iodine-131. It was also under development for the treatment of non-small cell lung cancer, breast cancer, soft tissue sarcoma, colorectal cancer, gastric cancer, prostate cancer, ovarian cancer and esophageal cancer.

Cellectar Biosciences overview

Cellectar Biosciences (Cellectar), is a biopharmaceutical company that discovers, develops and commercializes drugs for treatment of cancer. The company’s proprietary technology, phospholipid drug conjugates (PDC) delivery platform develops PDCs for the treatment and diagnosis of cancer. Its lead product, CLR 131, is a small-molecule PDC, in Phase II clinical trials for the treatment of relapse or refractory multiple myeloma and B-cell lymphomas. The company is also evaluating CLR 131 in Phase I clinical trials for treatment of Pediatric patients with solid tumors, lymphomas, malignant brain tumors, head and neck cancer. Cellectar’s other products in the pipeline include CLR 1800, CLR 1900, CLR 2000, CLR 2100, CLR 2200 and CLR 12120 for solid tumors and oncology indications. The company has collaborations with Orano Med, Onconova Therapeutics, Avicenna Oncology and University of Wisconsin. Cellectar is headquartered in Florham Park, New Jersey, the US.

Quick View Iopofosine i-131 LOA Data

Report Segments
  • Innovator
Drug Name
  • Iopofosine i-131
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.